Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330094 · ClinicalTrials.gov registry record · Phase 4
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
A Phase 4 study of Aneurysmal Subarachnoid Hemorrhage, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02330094: Completed Phase 4 study of Aneurysmal Subarachnoid Hemorrhage, sponsored by Mayo Clinic.
NCT02330094 is a Phase 4 study of Aneurysmal Subarachnoid Hemorrhage that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants, below the 345-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330094, a Phase 4 study of Aneurysmal Subarachnoid Hemorrhage, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.
Primary Outcome
Pain was measured on a Visual Analogue Scale (VAS) rated from 0-10, where 0 was no pain and 10 was the worst pain imaginable. The numeric pain score was measured every 4 hours and the total score over 24 hours was averaged as the daily numeric pain score. The daily scores were then averaged over a 7 day period for a single average pain score.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-09-01 |
| Phase | Phase 4 |
What the finished NCT02330094 record still lists
NCT02330094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 345-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Aneurysmal Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02330094 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02330094 about?
NCT02330094 is a clinical study titled "Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage". The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.
What is the current status of trial NCT02330094?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-09-01.
What conditions does trial NCT02330094 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT02330094?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT02330094?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330094 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysmal Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
RECRUITING · Phase 2
-
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
RECRUITING · Phase 1
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
-
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia